<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01409668</url>
  </required_header>
  <id_info>
    <org_study_id>B2007:070</org_study_id>
    <nct_id>NCT01409668</nct_id>
  </id_info>
  <brief_title>Efficacy of Two Yogurt Formulations in Healthy Humans</brief_title>
  <acronym>MPH</acronym>
  <official_title>Efficacy of Two Yogurt Formulations as Health Promoting Agents in Healthy Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Micropharma Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety and efficacy of consumption of: L.Ruteri containing&#xD;
      yogurt, L.Fermentum containing yogurt VERSUS placebo on plasma lipids, as well as&#xD;
      gastrointestinal microflora distribution in hyperlipidemic individuals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cholesterol Metabolism</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>L. Amylovorus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>L. Fermentum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L. Amylovorus</intervention_name>
    <description>L. Amylovorus</description>
    <arm_group_label>L. Amylovorus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L. Fermentum</intervention_name>
    <description>L. Fermentum</description>
    <arm_group_label>L. Fermentum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males and females&#xD;
&#xD;
          -  aged 18-60 yr&#xD;
&#xD;
          -  plasma LDL-C 130-260 mg/dl&#xD;
&#xD;
          -  TG levels below 400 mg/dl&#xD;
&#xD;
          -  body mass index (BMI) rangewill be 22 to 32 kg/m2&#xD;
&#xD;
          -  permitted to take stable doses of thyroid hormone and anti hypertensive agents, as&#xD;
             long as these are continued equivalently throughout the duration of study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of recent (i.e. less than 3 mo) or chronic use of oral hypolipidemic therapy,&#xD;
             including fish oils, or probucol within the last 6 mo, - history of chronic use of&#xD;
             alcohol (&gt;2 drinks/d), systemic antibodies, corticosteroids, androgens, or phenytoin,&#xD;
&#xD;
          -  myocardial infarction, coronary artery bypass, or other major surgical procedures&#xD;
             within the last six months&#xD;
&#xD;
          -  recent onset of angina, congestive heart failure, inflammatory bowel disease,&#xD;
             pancreatitis, diabetes, lactose intolerance or significant current (ie. onset within&#xD;
             past three months) gastrointestinal, renal, pulmonary, hepatic or biliary disease, or&#xD;
             cancer (evidence of active lesions, chemotherapy or surgery in the past year&#xD;
&#xD;
          -  chronic user of probiotics, fiber laxative (greater than 2 doses/wk), or stimulant&#xD;
             laxatives or has a history of eating disorders, exercise greater than 15 miles/wk or&#xD;
             4,000 kcal/wk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>June 22, 2011</study_first_submitted>
  <study_first_submitted_qc>August 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2011</study_first_posted>
  <last_update_submitted>August 3, 2011</last_update_submitted>
  <last_update_submitted_qc>August 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Peter Jones, Director of RCFFN</name_title>
    <organization>RCFFN, University of Manitoba</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

